Shenzhen Qianhai Capital led the funding round, with Shanghai Biomedical Industry Equity Investment Fund and Yuanbio Ventures jointly investing.
AccuPulse develops electrophysiology technology designed as a one-stop solution to treat cardiac arrhythmias, especially atrial fibrillation. Its product line includes an artificial intelligence (AI)-powered 3D mapping system, diagnostic and pulsed field ablation (PFA) catheters, a transseptal kit and an intracardiac ultrasound catheter to meet the requirements for electrophysiology surgery with zero radiation.
The company has previously raised a pre-Series A funding round of $8 million in November 2021 and opened new R&D centers in China and a U.S.-based one in Utah. AccuPulse said the funding round will finance the clinical trial of its PFA system and new product development.
“This is a solid step for AccuPulse in its drive to become a future leading electrophysiological platform company,” the company said in a news release.
